drugset / Trial / NCT03480906

Eyenovia MiDD Usability Study

NCT03480906

Completed 30 enrolled Eyenovia Inc.
Non-randomizedCrossoverSingle-blindOther

Summary

This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)

Timeline

Start
2018-03-12
Primary completion
2018-03-17
Completion
2018-03-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule Topical

Indications

No indication recorded.